Member Info for inanaco

clever answer .. however i know exactly what lindy is thinking .. Immunobody is to potent

Personalized neoepitope cancer vaccines
Sahin and colleagues have pioneered the use of individualized neoepitope mRNA cancer vaccines121. They use high-throughput sequencing to identify every unique somatic mutation of an individual patient’s tumour sample, termed the mutanome. This enables the rational design of neoepitope cancer vaccines in a patient-specific manner, and has the advantage of targeting non-self antigen specificities that should not be eliminated by central tolerance mechanisms. Proof of concept has been recently provided: Kreiter and colleagues found that a substantial portion of non-synonymous cancer mutations were immunogenic when delivered by mRNA and were mainly recognized by CD4+ T cells176. On the basis of these data, they generated a computational method to predict major histocompatibility complex (MHC) class II-restricted neoepitopes that can be used as vaccine immunogens. mRNA vaccines encoding such neoepitopes have controlled tumour growth in B16-F10 melanoma and CT26 colon cancer mouse models. In a recent clinical trial, Sahin and colleagues developed personalized neoepitope-based mRNA vaccines for 13 patients with metastatic melanoma, a cancer known for its high frequency of somatic mutations and thus neoepitopes. They immunized against ten neoepitopes per individual by injecting naked mRNA intranodally. CD4+ T cell responses were detected against the majority of the neoepitopes, and a low frequency of metastatic disease was observed after several months of follow-up68. Interestingly, similar results were also obtained in a study of analogous design that used synthetic peptides as immunogens rather than mRNA177. Together, these recent trials suggest the potential utility of the personalized vaccine methodology.

what i find intriguing ... Lindy and indeed trent .. have not even considered the RNA route .. for any cancer vaccine ... including

Moditope ..

good discovery ... wish they would indicate the cells in the VID and exactly what its doing .. a quick read gives little away

the science research paper titles don't mention DNA plasmids ... even thou RNA and DNA are similar .. both have to "go into" cells

10 to the 11 is 100 billion just in case algo appears

find a needle

Approximately 4 × 10 to the 11 T cells circulate in the adult human body ...

that is 100 billion ...

actually i had read that ... but did not see the "significance of the TB" rather i was looking at the Covid ..

but my thoughts are .... having a test that requires the "activation" of memory cells might not go down well in a pocket test ... health and safety issues

i was playing catch up ...... you should consider that i actually went back 24 hrs to read your posts ................ then the thread took off from yesterdays post not today's .. not even looked at them yet ... !!

T B is a chronic condition ? so are you not looking for active T cells .. ?

do you have a link ?

this is what i was saying about the TCR patent...... you end up with Multiple T cells even against the same target which are different .. this is then the T cell repertoire ... but this could be 100,000 or higher ..

only a clone is the same as the original ....

so any test has to consider the repertoire of TCR to the target .... so then the test has to deal with that tolerance

but also the consequences of the infection ........... memory cell repertoire

vaccination ............ the issue is if you have antibodies then you will also have a t cells response it all depends which route the vaccine takes ... because the B cells (those cells that secrete antibodies) can act as APC .... they only need a CD4 helper to activate so that then generates a cognitive T cell response .. from the B cell

maybe its best to find a very highly sensitive antibody test .... but then you may get false positives ..

IMHO a simple T cell test is not likely ...

may well have Bermuda ... but who took up the patent .. ?

however if you watched that display of advertising and showboating yesterday ... and Dawn Butlers efforts to challenge the GOV Advisors .. on "language" .... OMG ..

this thread is directed at bermuda from his post to Ray ... only just seen it .

"" and therapeutic interactions including viral challenge,""

Active immune therapies have shown promise in treating cancer and result in durable
responses in some patients. However they can also produce severe side effects as immune
responses against normal tissue may be generated. There is thus a need for an effective
biomarker to identify those patients most likely to respond to these therapies.
Greater T cell diversity has been linked with improved anti-tumour responses. The TCR is
formed by the rearrangement of germline encoded sequences, and includes one variable (V)
and one joining (J) gene sequence. The large number of V and J genes available allows the
generation of a very large TCR repertoire. TCR diversity naturally declines with age and can
also be reduced by pathological and therapeutic interactions including viral challenge,
immunisation, and immunosuppression from chemotherapy or bone marrow transplants.
ImmunTraCkeR®-Melanoma uses patented Multi-N-plex® PCR technology to qualify and
quantify the relative amount of each different V-J combination and thus the diversity of the
TCR repertoire. In this way, ImmunTraCkeR®-Melanoma can assess the patient’s eligibility
for treatment (based on their immune status) prior to treatment with immune checkpoint
inhibitors. ImmunTraCkeR®-Melanoma may also:
? Establish a baseline immune profile to enable treatment to be tailored as patients
with different baseline immune profiles may respond differently.
? Monitor immune profile changes under treatment.
? Help identify patients unlikely to respond to immunotherapy, therefore avoiding the
use of expensive but ineffective treatments and their associated side effects.

can they tighten the parameters ... ?

I can see why that would interest you ..... in that the Gov track and test ... in fact the worlds system for track and test is probably missing the "infectious" that have a cd4/cd8 t cell response with a weak b cell response .. in which case its an open market. However its a serious amount of work to find those signature T cells ..indeed the scib1 test that panel .. could be adapted

ImmunID has been a pioneer in the field of immune molecular diagnostics for a decade. Its clinical product ImmunTraCkeR® evaluates a patient’s immune status, from a simple liquid biopsy (5ml EDTA blood), based on T lymphocyte repertoire diversity. ImmunID has developed and patented the ImmunTraCkeR® diagnostic assay and is expanding its clinical utility to become the general immune companion diagnostics for all immune therapies and especially immune checkpoint agents.

so basically it could be adapted to track the repertoire of cronovirus infections so you could get a background from previous indicating cross reactivity in people that have not been infected and the more specific of covid itself ...

extremely useful if you could predict disease progression from it ... ie identify cross reactivity as well

or Vals then

Thanks for that ........... maybe members of that should be a target for emails ... Scancell falls perfectly inline with Gov Policy

Chair of the House of Commons Science and Technology Select Committee, Greg Clark MP, has responded to this morning's speech from Prime Minister Boris Johnson.

Inquiry: A new UK research funding agency
Science and Technology Committee
The speech included measures relating to science and innovation, including:

the creation of a new science funding agency to back 'high-risk, high-reward projects';
the ambition to make the UK a 'science superpower'; and
the commitment to end the 'chasm' between intention and application, which can lead to a brain drain from UK soil.
Chair's comments
Chair of the Science and Technology Committee, Greg Clark MP, said:

"I welcome the prominence of science and innovation in today's speech from the Prime Minister. My Committee’s ongoing work relating to the COVID-19 pandemic has demonstrated just how indispensable, and how world-leading, science, research and innovation are in the UK. Innovation across every scientific discipline will play a critical role in economic recovery, making its place at the centre of recovery plans more essential than ever.

“My Committee has already launched an inquiry on the Government’s plans for a new science funding agency and we will hold oral hearings in the weeks ahead.”

come on Dick expand your horizons past "tits Up"